IL15 and T-cell stemness in T-cell-based cancer immunotherapy

Karolina Pilipow, Alessandra Roberto, Mario Roederer, Thomas A. Waldmann, Domenico Mavilio, Enrico Lugli

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Preclinical models revealed that the immune system can mediate rejection of established tumors, but direct evidence in humans has been limited to largely immunogenic tumors, such as melanoma. The recent success of immune checkpoint inhibitors and adoptive T-cell transfer immunotherapy in clinical trials has instilled new hope for the use of T-cell immunotherapy in the treatment of cancer. IL15, a potent immunostimulatory cytokine, both potentiates host T-cells and natural killer (NK) cell immune responses and promotes the generation of long-lived memory T cells with superior functional capacity, with potential use in adoptive T-cell transfer protocols. IL15 has been recently tested in the clinic and showed dramatic effects at the level of responding NK and CD8+ memory T cells. The recent advances in the knowledge of IL15-dependent regulation of T-cell responses, gene expression, and metabolic adaptation have important implications for the use of IL15 in T-cell-based immunotherapy of cancer.

Original languageEnglish
Pages (from-to)5187-5193
Number of pages7
JournalCancer Research
Volume75
Issue number24
DOIs
Publication statusPublished - Dec 15 2015

Fingerprint

Interleukin-15
Immunotherapy
T-Lymphocytes
Neoplasms
Adoptive Transfer
Natural Killer Cells
Immune System
Melanoma
Clinical Trials
Cytokines
Gene Expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

IL15 and T-cell stemness in T-cell-based cancer immunotherapy. / Pilipow, Karolina; Roberto, Alessandra; Roederer, Mario; Waldmann, Thomas A.; Mavilio, Domenico; Lugli, Enrico.

In: Cancer Research, Vol. 75, No. 24, 15.12.2015, p. 5187-5193.

Research output: Contribution to journalArticle

Pilipow, Karolina ; Roberto, Alessandra ; Roederer, Mario ; Waldmann, Thomas A. ; Mavilio, Domenico ; Lugli, Enrico. / IL15 and T-cell stemness in T-cell-based cancer immunotherapy. In: Cancer Research. 2015 ; Vol. 75, No. 24. pp. 5187-5193.
@article{39ebdf10e78b41658c05af825ce668ea,
title = "IL15 and T-cell stemness in T-cell-based cancer immunotherapy",
abstract = "Preclinical models revealed that the immune system can mediate rejection of established tumors, but direct evidence in humans has been limited to largely immunogenic tumors, such as melanoma. The recent success of immune checkpoint inhibitors and adoptive T-cell transfer immunotherapy in clinical trials has instilled new hope for the use of T-cell immunotherapy in the treatment of cancer. IL15, a potent immunostimulatory cytokine, both potentiates host T-cells and natural killer (NK) cell immune responses and promotes the generation of long-lived memory T cells with superior functional capacity, with potential use in adoptive T-cell transfer protocols. IL15 has been recently tested in the clinic and showed dramatic effects at the level of responding NK and CD8+ memory T cells. The recent advances in the knowledge of IL15-dependent regulation of T-cell responses, gene expression, and metabolic adaptation have important implications for the use of IL15 in T-cell-based immunotherapy of cancer.",
author = "Karolina Pilipow and Alessandra Roberto and Mario Roederer and Waldmann, {Thomas A.} and Domenico Mavilio and Enrico Lugli",
year = "2015",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-15-1498",
language = "English",
volume = "75",
pages = "5187--5193",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - IL15 and T-cell stemness in T-cell-based cancer immunotherapy

AU - Pilipow, Karolina

AU - Roberto, Alessandra

AU - Roederer, Mario

AU - Waldmann, Thomas A.

AU - Mavilio, Domenico

AU - Lugli, Enrico

PY - 2015/12/15

Y1 - 2015/12/15

N2 - Preclinical models revealed that the immune system can mediate rejection of established tumors, but direct evidence in humans has been limited to largely immunogenic tumors, such as melanoma. The recent success of immune checkpoint inhibitors and adoptive T-cell transfer immunotherapy in clinical trials has instilled new hope for the use of T-cell immunotherapy in the treatment of cancer. IL15, a potent immunostimulatory cytokine, both potentiates host T-cells and natural killer (NK) cell immune responses and promotes the generation of long-lived memory T cells with superior functional capacity, with potential use in adoptive T-cell transfer protocols. IL15 has been recently tested in the clinic and showed dramatic effects at the level of responding NK and CD8+ memory T cells. The recent advances in the knowledge of IL15-dependent regulation of T-cell responses, gene expression, and metabolic adaptation have important implications for the use of IL15 in T-cell-based immunotherapy of cancer.

AB - Preclinical models revealed that the immune system can mediate rejection of established tumors, but direct evidence in humans has been limited to largely immunogenic tumors, such as melanoma. The recent success of immune checkpoint inhibitors and adoptive T-cell transfer immunotherapy in clinical trials has instilled new hope for the use of T-cell immunotherapy in the treatment of cancer. IL15, a potent immunostimulatory cytokine, both potentiates host T-cells and natural killer (NK) cell immune responses and promotes the generation of long-lived memory T cells with superior functional capacity, with potential use in adoptive T-cell transfer protocols. IL15 has been recently tested in the clinic and showed dramatic effects at the level of responding NK and CD8+ memory T cells. The recent advances in the knowledge of IL15-dependent regulation of T-cell responses, gene expression, and metabolic adaptation have important implications for the use of IL15 in T-cell-based immunotherapy of cancer.

UR - http://www.scopus.com/inward/record.url?scp=84955294718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955294718&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-1498

DO - 10.1158/0008-5472.CAN-15-1498

M3 - Article

VL - 75

SP - 5187

EP - 5193

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 24

ER -